LTRN.US Lantern Pharma Inc

Healthcare Biotechnology USA Stocks
0.4331 USD
Close of Nov 15, 2026
0.3821 4.34
Market cap
USD 6.47M
P/E
-
P/B
9.74x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is LTRN.US undervalued?

Graham number

The Graham number of Lantern Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lantern Pharma Inc fundamental analysis

No fundamental analysis for Lantern Pharma Inc yet.

Lantern Pharma Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lantern Pharma Inc

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma …

Full company profile